Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.

Aurelius J, Möllgård L, Kiffin R, Ewald Sander F, Nilsson S, Bergh Thorén F, Hellstrand K, Martner A.

Leuk Lymphoma. 2019 Apr 17:1-8. doi: 10.1080/10428194.2019.1599110. [Epub ahead of print]

PMID:
30991860
2.

The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Hallner A, Bernson E, Hussein BA, Ewald Sander F, Brune M, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Blood. 2019 Mar 28;133(13):1479-1488. doi: 10.1182/blood-2018-09-874990. Epub 2019 Jan 15.

3.

Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.

Bernson E, Hallner A, Sander FE, Nicklasson M, Nilsson MS, Christenson K, Aydin E, Liljeqvist JÅ, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Cancer Immunol Res. 2018 Sep;6(9):1110-1119. doi: 10.1158/2326-6066.CIR-17-0711. Epub 2018 Jul 6.

4.

Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.

Kiffin R, Grauers Wiktorin H, Nilsson MS, Aurelius J, Aydin E, Lenox B, Nilsson JA, Ståhlberg A, Thorén FB, Hellstrand K, Martner A.

Front Oncol. 2018 Jun 18;8:218. doi: 10.3389/fonc.2018.00218. eCollection 2018.

5.

Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.

Sander FE, Nilsson M, Rydström A, Aurelius J, Riise RE, Movitz C, Bernson E, Kiffin R, Ståhlberg A, Brune M, Foà R, Hellstrand K, Thorén FB, Martner A.

Cancer Immunol Immunother. 2017 Nov;66(11):1473-1484. doi: 10.1007/s00262-017-2040-9. Epub 2017 Jul 18.

6.

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.

Bernson E, Hallner A, Sander FE, Wilsson O, Werlenius O, Rydström A, Kiffin R, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Leukemia. 2017 Dec;31(12):2552-2559. doi: 10.1038/leu.2017.151. Epub 2017 May 22.

7.

NOX2-dependent immunosuppression in chronic myelomonocytic leukemia.

Aurelius J, Hallner A, Werlenius O, Riise R, Möllgård L, Brune M, Hansson M, Martner A, Thorén FB, Hellstrand K.

J Leukoc Biol. 2017 Aug;102(2):459-466. doi: 10.1189/jlb.5VMA1116-454R. Epub 2017 Mar 14.

PMID:
28292946
8.

Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.

Rydström A, Hallner A, Aurelius J, Sander FE, Bernson E, Kiffin R, Thoren FB, Hellstrand K, Martner A.

J Leukoc Biol. 2017 Aug;102(2):467-474. doi: 10.1189/jlb.5VMA1116-455R. Epub 2017 Feb 24.

PMID:
28235771
9.

Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.

Werlenius O, Aurelius J, Hallner A, Akhiani AA, Simpanen M, Martner A, Andersson PO, Hellstrand K, Thorén FB.

Oncotarget. 2016 May 31;7(22):32046-53. doi: 10.18632/oncotarget.8769.

10.

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Martner A, Rydström A, Riise RE, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB.

Oncoimmunology. 2015 May 5;5(1):e1041701. doi: 10.1080/2162402X.2015.1041701. eCollection 2016.

11.

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.

Sander FE, Rydström A, Bernson E, Kiffin R, Riise R, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB, Martner A.

Oncotarget. 2016 Feb 16;7(7):7586-96. doi: 10.18632/oncotarget.7210.

12.

NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.

Martner A, Rydström A, Riise RE, Aurelius J, Brune M, Foà R, Hellstrand K, Thorén FB.

Oncotarget. 2015 Dec 15;6(40):42569-74. doi: 10.18632/oncotarget.5559.

13.

TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses.

Riise RE, Bernson E, Aurelius J, Martner A, Pesce S, Della Chiesa M, Marcenaro E, Bylund J, Hellstrand K, Moretta L, Moretta A, Thorén FB.

J Immunol. 2015 Aug 1;195(3):1121-8. doi: 10.4049/jimmunol.1500709. Epub 2015 Jun 17.

14.

Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase.

Martner A, Wiktorin HG, Lenox B, Ewald Sander F, Aydin E, Aurelius J, Thorén FB, Ståhlberg A, Hermodsson S, Hellstrand K.

J Immunol. 2015 May 15;194(10):5014-21. doi: 10.4049/jimmunol.1402991. Epub 2015 Apr 13.

15.

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 favors sustained lymphocyte recovery in acute myeloid leukemia.

Hallner A, Aurelius J, Thorén FB, Sander FE, Brune M, Hellstrand K, Martner A.

Eur J Haematol. 2015 Mar;94(3):279-80. doi: 10.1111/ejh.12454. Epub 2014 Nov 21. No abstract available. Erratum in: Eur J Haematol. 2019 Jan;102(1):99.

PMID:
25256820
16.

CD20 antibodies induce production and release of reactive oxygen species by neutrophils.

Werlenius O, Riise RE, Simpanen M, Aurelius J, Thorén FB.

Blood. 2014 Jun 19;123(25):4001-2. doi: 10.1182/blood-2014-05-574285. No abstract available.

17.

Role of the ERK pathway for oxidant-induced parthanatos in human lymphocytes.

Akhiani AA, Werlenius O, Aurelius J, Movitz C, Martner A, Hellstrand K, Thorén FB.

PLoS One. 2014 Feb 21;9(2):e89646. doi: 10.1371/journal.pone.0089646. eCollection 2014.

18.

Immunotherapeutic strategies for relapse control in acute myeloid leukemia.

Martner A, Thorén FB, Aurelius J, Hellstrand K.

Blood Rev. 2013 Sep;27(5):209-16. doi: 10.1016/j.blre.2013.06.006. Epub 2013 Jul 18. Review.

PMID:
23871358
19.

Virus-induced appearance of the selectin ligand sLeX in herpes simplex virus type 1-infected T-cells: involvement of host and viral factors.

Nordén R, Nyström K, Aurelius J, Brisslert M, Olofsson S.

Glycobiology. 2013 Mar;23(3):310-21. doi: 10.1093/glycob/cws160. Epub 2012 Nov 9.

PMID:
23144050
20.

Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes.

Aurelius J, Martner A, Riise RE, Romero AI, Palmqvist L, Brune M, Hellstrand K, Thorén FB.

J Leukoc Biol. 2013 Jan;93(1):155-60. doi: 10.1189/jlb.0512257. Epub 2012 Oct 16.

PMID:
23072905
21.

Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.

Aurelius J, Martner A, Brune M, Palmqvist L, Hansson M, Hellstrand K, Thoren FB.

Haematologica. 2012 Dec;97(12):1904-8. doi: 10.3324/haematol.2012.066399. Epub 2012 Jun 11.

22.

Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis.

Aurelius J, Thorén FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, Hellstrand K, Martner A.

Blood. 2012 Jun 14;119(24):5832-7. doi: 10.1182/blood-2011-11-391722. Epub 2012 May 1.

23.

Redox remodeling by dendritic cells protects antigen-specific T cells against oxidative stress.

Martner A, Aurelius J, Rydström A, Hellstrand K, Thorén FB.

J Immunol. 2011 Dec 15;187(12):6243-8. doi: 10.4049/jimmunol.1102138. Epub 2011 Nov 16.

24.

Antitumor properties of histamine in vivo.

Thoren FB, Aurelius J, Martner A.

Nat Med. 2011 May;17(5):537; author reply 537-8. doi: 10.1038/nm0511-537a. No abstract available.

PMID:
21546964
25.

Defining cell populations with single-cell gene expression profiling: correlations and identification of astrocyte subpopulations.

Ståhlberg A, Andersson D, Aurelius J, Faiz M, Pekna M, Kubista M, Pekny M.

Nucleic Acids Res. 2011 Mar;39(4):e24. doi: 10.1093/nar/gkq1182. Epub 2010 Nov 25.

26.

Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.

Martner A, Thorén FB, Aurelius J, Söderholm J, Brune M, Hellstrand K.

Expert Rev Hematol. 2010 Aug;3(4):381-91. doi: 10.1586/ehm.10.30. Review.

PMID:
21083028
27.

Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.

Romero AI, Thorén FB, Aurelius J, Askarieh G, Brune M, Hellstrand K.

Scand J Immunol. 2009 Sep;70(3):194-205. doi: 10.1111/j.1365-3083.2009.02303.x. Review.

28.

The low back problem--an evaluation.

Kosiak M, Aurelius JR, Hartfiel WF.

J Occup Med. 1968 Oct;10(10):588-93. No abstract available.

PMID:
4234913
29.

Backache in industry.

Kosiak M, Aurelius JR, Hartfiel WF.

J Occup Med. 1966 Feb;8(2):51-8. No abstract available.

PMID:
4221782
30.

PSEUDOHYPOPARATHYROIDISM. FOLLOWUP OVER A 26 YEAR PERIOD.

KIEFFER SA, PETERSON DH, AURELIUS JR.

Minn Med. 1965 Jan;48:9-13. No abstract available.

PMID:
14244300
31.

The current status of bronchography with water-soluble media; a report of 74 examinations with xumbradil viscous B.

NIKNEJAD I, AURELIUS JR, PETERSON DH, RIGLER LG.

Am J Roentgenol Radium Ther Nucl Med. 1956 Apr;75(4):701-19. No abstract available.

PMID:
13302534
32.

Retroperitoneal cavernous hemangioma associated with hemangiomas of the skin in a newborn; case report and brief review of literature.

AURELIUS JR, PETERSON DH, NIKNEJAD I.

Minn Med. 1955 Jan;38(1):32-7. No abstract available.

PMID:
13235615
33.

Emphysematous cholecystitis.

FRIEDMAN J, AURELIUS JR, RIGLER LG.

Am J Roentgenol Radium Ther. 1949 Dec;62(6):814-22, illust. No abstract available.

PMID:
15396494
34.

Problems in the X-ray diagnosis of pulmonary tuberculosis.

AURELIUS JR.

Minn Med. 1949 Nov;32(11):1133-6. No abstract available.

PMID:
15406629

Supplemental Content

Loading ...
Support Center